^
    Apply
    TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT06106841)
    Phase 1/2
    Chia Tai Tianqing Pharmaceutical Group Nanjing ...
    Recruiting
    Last update posted :
    10/30/2023
    Initiation :
    10/05/2023
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BCL2
    |
    TQB3909
    A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (NCT05959694)
    Phase 1/2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    10/11/2023
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    PLCG2
    |
    TQB3909
    A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (NCT05775575)
    Phase 1/2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    03/20/2023
    Initiation :
    03/02/2023
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    TQB3909
    A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (NCT04975204)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    03/07/2022
    Initiation :
    02/18/2022
    Primary completion :
    12/01/2022
    Completion :
    08/01/2024
    BCL2
    |
    BCL2 expression
    |
    TQB3909